Opdivo Reimbursement Rejected In Scotland
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's skin cancer therapy, Opdivo (nivolumab), has been rejected for use on the Scottish National Health System – an unusual decision considering the drug's recent approval for use in England and Wales.